Advantages of sensor-augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus.

Autor: Imafuku H; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Tanimura K; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Masuko N; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Tomimoto M; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Shi Y; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Uchida A; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Deguchi M; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan., Fujioka K; Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan., Yamamoto A; Division of Diabetes and Endocrinology, Department of the Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan., Yoshino K; Division of Diabetes and Endocrinology, Department of the Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan., Hirota Y; Division of Diabetes and Endocrinology, Department of the Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan., Ogawa W; Division of Diabetes and Endocrinology, Department of the Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan., Terai Y; Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Jazyk: angličtina
Zdroj: Journal of diabetes investigation [J Diabetes Investig] 2023 Dec; Vol. 14 (12), pp. 1383-1390. Date of Electronic Publication: 2023 Sep 14.
DOI: 10.1111/jdi.14075
Abstrakt: Aims/introduction: To evaluate the efficacy of sensor-augmented pump (SAP) for improving obstetric and neonatal outcomes among pregnant women with type 1 diabetes mellitus by comparing it with continuous subcutaneous insulin infusion plus self-monitoring of blood glucose (continuous subcutaneous insulin infusion [CSII]/SMBG).
Materials and Methods: This retrospective cohort study included 40 cases of pregnancy complicated by type 1 diabetes mellitus treated with SAP (SAP group), and 29 cases of pregnancy complicated by type 1 diabetes mellitus treated with CSII/SMBG (CSII/SMBG group). The obstetric and neonatal outcomes were compared between the two groups.
Results: The median of the glycoalbumin levels in the first (18.8% vs 20.9%; P < 0.05) and second (15.4% vs 18.0%; P < 0.05) trimesters, the hemoglobin A1c levels in the peripartum period (6.1% vs 6.5%; P < 0.05) and the standard deviation score of birthweights (0.36 vs 1.52; P < 0.05) were significantly lower in the SAP group than in the CSII/SMBG group. The incidence rate of large for gestational age newborns was significantly lower in the SAP group than in the CSII/SMBG group (27.5% vs 65.5%; P < 0.05). No significant differences in the incidence rates of hypertensive disorders of pregnancy, small for gestational age, respiratory distress syndrome, neonatal hypoglycemia, hypervolemia and hyperbilirubinemia were observed between the groups.
Conclusion: The present study showed that SAP therapy is more effective in preventing large for gestational age newborns in pregnant women with type 1 diabetes mellitus than CSII/SMBG.
(© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje